title: Botulinum toxin type B (MyoBloc) in the management of hyperkinetic facial lines.
abstract: OBJECTIVE
  Our goal was to evaluate the safety and efficacy of botulinum toxin type B (BTX-B) in the management of hyperfunctional facial lines.
  
  
  METHODS
  Twenty-four patients from an academic faculty practice were treated with 400 to 800 units BTX-B in the corrugator, orbicularis oculi, or frontalis. Patients were evaluated with the Wrinkle Improvement Score (WIS) and Rated Numeric Kinetic Line Scale (RNKLS) and questioned about side effects and pain. Evaluations were made at 1, 2, 4, 8, and 12 weeks.
  
  
  RESULTS
  Onset of effect was within 72 hours. WIS and RNKLS for all sites were statistically better after treatment, with the effect lasting 8 weeks. In general, patients noted a moderate improvement (grade 2) on WIS and a 2-point improvement on RNKLS. Injection was more painful than that of BTX-A. There were no complications.
  
  
  CONCLUSIONS
  BTX-B is a safe and effective technique to eliminate wrinkles. Further studies are needed to elucidate dosage and duration.
  
  
  CONCLUSIONS
  BTX-B is stable for prolonged periods of time, requires no preparation before use, and is antigenetically distinct from BTX-A.
authors.affiliation: Division of Facial Plastic and Reconstructive Surgery, Department of Otolaryngology-Head and Neck Surgery, University of California, San Francisco, CA 94115, USA.
authors.forename: Alexander L
authors.initials: AL
authors.lastname: Ramirez
authors.forename: Jay
authors.initials: J
authors.lastname: Reeck
authors.forename: Corey S
authors.initials: CS
authors.lastname: Maas
mesh_terms: D000328:Adult; D001905:Botulinum Toxins / Q000009:adverse effects / Q000493:pharmacokinetics / Q000627:therapeutic use*; D019274:Botulinum Toxins, Type A; D005260:Female; D005868:Gestures; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000209:etiology / Q000503:physiopathology; D010147:Pain Measurement; D010865:Pilot Projects; D015595:Skin Aging / Q000187:drug effects* / Q000502:physiology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: C096323:rimabotulinumtoxinB; D001905:Botulinum Toxins; D019274:Botulinum Toxins, Type A